Synonyms: AZD1061 | COV2-2130 | Evusheld® (tixagevimab + cilgavimab)
Compound class:
Antibody
Comment: Cilgavimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [2]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. It is designed to be a long-acting agent, and in combination with tixagevimab (co-packaged combination= Evusheld®), is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised [1]. Data from the Phase 3 PROVENT trial (NCT04625725) show protection from infection that lasts for at least six months. AstraZeneca have reported that Evusheld® retains neutralising activity against the omicron (B.1.1.529) SARS-CoV-2 variant.
|
Classification ![]() |
|
Compound class | Antibody |
International Nonproprietary Names ![]() |
|
INN number | INN |
11777 | cilgavimab |
Synonyms ![]() |
AZD1061 | COV2-2130 | Evusheld® (tixagevimab + cilgavimab) |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 1106 |
Other databases | |
GtoPdb PubChem SID | 434321764 |
Search PubMed clinical trials | cilgavimab |
Search PubMed titles | cilgavimab |
Search PubMed titles/abstracts | cilgavimab |